1. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. (September 2017) Authors: Shen, Lan; Niu, Xiaomin; Jian, Hong; Xu, Yunhua; Yu, Yongfeng; Lu, Shun Journal: Lung cancer Issue: Volume 111(2017) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling. Issue 4 (10th March 2017) Authors: Zhao, Yi; Yang, Yi; Xu, Yunhua; Lu, Shun; Jian, Hong Journal: FEBS open bio Issue: Volume 7:Issue 4(2017) Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Coping, mood and health-related quality of life: a cross-sectional study in Chinese patients with advanced lung cancer. Issue 5 (5th May 2019) Authors: He, Yaping; Jian, Hong; Yan, Meiqiong; Zhu, Jingfen; Li, Guohong; Lou, Vivian W Q; Chen, Jieling Journal: BMJ open Issue: Volume 9:Issue 5(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report. Issue 47 (25th November 2022) Authors: Gu, Linping; Ji, Wenxiang; Xu, Yunhua; Han, Yuchen; Jian, Hong Journal: Medicine Issue: Volume 101:Issue 47(2022) Page Start: e31480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. Issue 8 (September 2019) Authors: Jian, Hong; Han, Yuchen; Yu, Yongfeng; Lu, Shun Journal: Anti-cancer drugs Issue: Volume 30:Issue 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer. (26th February 2022) Authors: Jian, Hong; Wang, Kai; Cheng, Ying; Ding, Lieming; Wang, Yang; Shi, Zhe; Zhang, Ling; Wang, Yaolin; Lu, Shun Journal: Oncologist Issue: Volume 27:Number 3(2022) Page Start: 163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. (25th July 2016) Authors: Yu, Yongfeng; Ding, Zhengping; Jian, Hong; Shen, Lan; Zhu, Lei; Lu, Shun Journal: Cancer medicine Issue: Volume 5:Number 9(2016:Sep.) Page Start: 2323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Reduced expression of FXYD domain containing ion transport regulator 5 (FXYD5) in association with hypertension. (12th October 2011) Authors: Xiaoyan, Huang; Xaingxiang, Shi; Jian, Hong; Xi, Zhou; Yong-jian, Geng Journal: Heart Issue: Volume 97(2011)Supplement 3 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Shape‐ and Size‐Controlled Synthesis of Mn3O4 Nanocrystals at Room Temperature. Issue 19 (27th May 2014) Authors: Chen, Chao; Jian, Hong; Mai, Kaiguang; Ren, Zhimin; Wang, Jia; Fu, Xinxin; Fan, Chenyao; Sun, Chunxiao; Qian, Guodong; Wang, Zhiyu Journal: European journal of inorganic chemistry Issue: Issue 19(2014) Page Start: 3023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Issue 9 (September 2022) Authors: Lu, Shun; Wu, Lin; Jian, Hong; Chen, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Sun, Meili; Han, Liang; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Li, Baolan; Pan, Yueyin; Li, Xingya; Ye, Feng; Liu, Anwen; Wang, Ke; Cang, Shundong Journal: Lancet oncology Issue: Volume 23:Issue 9(2022) Page Start: 1167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗